The significance of antibody to hepatitis B surface antigen in infection and clearance of hepatitis B virus
Authors:
Open Access
- 3 January 2025
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 21 (1) , 2445283
Abstract
One of the key features of chronic hepatitis B virus (HBV) infection is the inability to mount sufficient and coordinated adaptive immune responses against HBV. Recent studies on HBV-specific B cells and antibody to hepatitis B surface antigen (anti-HBs) have shed light on their role in the pathogenesis of chronic hepatitis B (CHB). Anti-HBs is recognized as a protective immune marker, both for HBV infection clearance and following vaccination, and it is also considered an important indicator of functional cure for CHB. Notably, functional impairment of HBV-specific B cells may be reversible. The restoration of HBV-specific B cell function, along with the induction of an anti-HBs antibody response, is regarded as pivotal for terminating chronic HBV infection and achieving functional cure. This article reviews the significance of anti-HBs in both the infection and clearance of HBV, and discusses the potential of neutralizing antibodies and therapeutic vaccines as promising future strategies.Keywords
Funding Information
- National Science and Technology Major Project (no. 2018ZX10302204-001)
This publication has 99 references indexed in Scilit:
- Single‐cell RNA sequencing reveals reduced intercellular adhesion molecule crosstalk between activated hepatic stellate cells and neutrophils alleviating liver fibrosis in hepatitis B virus transgenic mice post menstrual blood‐derived mesenchymal stem cell transplantationMedcomm, 2024
- Elimination of the hepatitis B virus: A goal, a challengeMedicinal Research Reviews, 2024
- Association of Coexistent Hepatitis B Surface Antigen and Antibody With Severe Liver Fibrosis and Cirrhosis in Treatment-Naive Patients With Chronic Hepatitis BJAMA Network Open, 2022
- Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trialHepatology, 2021
- Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidanceHepatology, 2018
- Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infectionJournal of Gastroenterology, 2016
- Novel Mechanism of Antibodies to Hepatitis B Virus in Blocking Viral Particle Release from Cells†Hepatology, 2010
- Hepatitis B virus suppresses toll-like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells #Hepatology, 2009
- In vivo kinetics and biodistribution of HB-110, a novel HBV DNA vaccine, after administration in mice.Archives of Pharmacal Research, 2007
- Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre‐treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexesJournal of Medical Virology, 2001